BeiGene Return on Tangible Equity 2014-2024 | ONC
Current and historical return on tangible equity values for BeiGene (ONC) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| BeiGene Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-09-30 |
$-0.86B |
$3.38B |
-25.52% |
| 2024-06-30 |
$-0.52B |
$3.31B |
-15.18% |
| 2024-03-31 |
$-0.79B |
$3.31B |
-22.04% |
| 2023-12-31 |
$-0.88B |
$3.48B |
-23.43% |
| 2023-09-30 |
$-0.96B |
$3.71B |
-24.09% |
| 2023-06-30 |
$-1.73B |
$3.75B |
-41.17% |
| 2023-03-31 |
$-1.92B |
$4.12B |
-41.82% |
| 2022-12-31 |
$-2.00B |
$4.34B |
-39.97% |
| 2022-09-30 |
$-2.17B |
$4.61B |
-39.73% |
| 2022-06-30 |
$-2.05B |
$5.26B |
-39.85% |
| 2022-03-31 |
$-1.96B |
$5.84B |
-41.54% |
| 2021-12-31 |
$-1.46B |
$6.09B |
-34.26% |
| 2021-09-30 |
$-1.33B |
$3.34B |
-35.81% |
| 2021-06-30 |
$-1.31B |
$3.60B |
-33.32% |
| 2021-03-31 |
$-1.17B |
$4.00B |
-31.77% |
| 2020-12-31 |
$-1.60B |
$3.86B |
-47.26% |
| 2020-09-30 |
$-1.51B |
$4.29B |
-56.92% |
| 2020-06-30 |
$-1.39B |
$2.54B |
-73.15% |
| 2020-03-31 |
$-1.15B |
$2.82B |
-68.90% |
| 2019-12-31 |
$-0.95B |
$0.97B |
-69.75% |
| 2019-09-30 |
$-0.83B |
$1.29B |
-53.74% |
| 2019-06-30 |
$-0.67B |
$1.57B |
-38.91% |
| 2019-03-31 |
$-0.74B |
$1.62B |
-45.43% |
| 2018-12-31 |
$-0.67B |
$1.70B |
-43.40% |
| 2018-09-30 |
$-0.51B |
$1.96B |
-39.03% |
| 2018-06-30 |
$-0.24B |
$1.21B |
-24.68% |
| 2018-03-31 |
$-0.15B |
$1.34B |
-19.63% |
| 2017-12-31 |
$-0.09B |
$0.66B |
-18.94% |
| 2017-09-30 |
$-0.03B |
$0.74B |
-7.89% |
| 2017-06-30 |
$-0.19B |
$0.27B |
-66.13% |
| 2017-03-31 |
$-0.15B |
$0.31B |
-55.38% |
| 2016-12-31 |
$-0.12B |
$0.35B |
-47.41% |
| 2016-09-30 |
$-0.11B |
$0.19B |
-59.59% |
| 2016-06-30 |
$-0.08B |
$0.22B |
-58.85% |
| 2016-03-31 |
$-0.07B |
$0.24B |
-82.02% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
